Louise Burrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8073505/publications.pdf Version: 2024-02-01



LOUISE RUDDEU

#	Article	IF	CITATIONS
1	Retinal microvascular function predicts chronic kidney disease in patients with cardiovascular risk factors. Atherosclerosis, 2022, 341, 63-70.	0.8	3
2	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, 2022, 23, 210-216.	14.5	486
3	Improved tissue preparation for multimodal vibrational imaging of biological tissues. Clinical Spectroscopy, 2022, 4, 100021.	1.3	3
4	Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 resplraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial. Trials, 2022, 23, 361.	1.6	2
5	The Need for Individualized Risk Assessment in Cardiovascular Disease. Journal of Personalized Medicine, 2022, 12, 1140.	2.5	4
6	A deep-learning system for the assessment of cardiovascular disease risk via the measurement of retinal-vessel calibre. Nature Biomedical Engineering, 2021, 5, 498-508.	22.5	131
7	Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular disease. Cardiovascular Research, 2021, 117, 1949-1957.	3.8	27
8	Incidental Thoracic Aortic Dilation on Chest Computed Tomography in Patients With Atrial Fibrillation. American Journal of Cardiology, 2021, 140, 78-82.	1.6	9
9	Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?. Journal of Thrombosis and Thrombolysis, 2021, 52, 610-619.	2.1	10
10	Excess mortality at Christmas due to cardiovascular disease in the HUNT study prospective population-based cohort in Norway. BMC Public Health, 2021, 21, 549.	2.9	7
11	Novel Approach to Risk Stratification in Left Ventricular Non ompaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach. Journal of the American Heart Association, 2021, 10, e019209.	3.7	12
12	Systematic quantification of histologic ventricular fibrosis in isolated mitral valve prolapse and sudden cardiac death. Heart Rhythm, 2021, 18, 570-576.	0.7	21
13	Renal ACE2 (Angiotensin-Converting Enzyme 2) Expression Is Modulated by Dietary Fiber Intake, Gut Microbiota, and Their Metabolites. Hypertension, 2021, 77, e53-e55.	2.7	9
14	Angiotensin-Converting Enzyme 2 Activity Is Associated With Embolic Stroke of Undetermined Source. Stroke, 2021, 52, e324-e325.	2.0	0
15	Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial. Trials, 2021, 22, 573.	1.6	7
16	Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. European Respiratory Journal, 2021, 57, 2003730.	6.7	100
17	No dynamic changes in plasma ACE2 activity in patients with acute coronary syndrome. European Heart Journal, 2021, 42,	2.2	0
18	Comparison of white matter hyperintensity abnormalities and cognitive performance in individuals with low and high cardiovascular risk: Data from the Diabetes and Dementia (D2) study. Alzheimer's and Dementia, 2021, 17, .	0.8	1

#	Article	IF	CITATIONS
19	Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. Gut, 2020, 69, 841-851.	12.1	160
20	Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis. JACC: Cardiovascular Imaging, 2020, 13, 655-664.	5.3	88
21	Circulating ACE2: a novel biomarker of cardiovascular risk. Lancet, The, 2020, 396, 937-939.	13.7	24
22	May Measurement Month 2018: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2020, 22, H17-H19.	0.1	4
23	Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. European Heart Journal, 2020, 41, 4580-4588.	2.2	41
24	Renin–angiotensin system inhibition and risk of infection and mortality in COVIDâ€19: a systematic review and metaâ€analysis. Internal Medicine Journal, 2020, 50, 1468-1474.	0.8	15
25	Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems in Cardiology, 2020, 45, 100653.	2.4	2
26	Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis. Hepatology International, 2020, 14, 884-885.	4.2	8
27	Rigor before speculation in COVID-19 therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1027-L1028.	2.9	3
28	Plasma Cortisol, Aldosterone, and Ascorbic Acid Concentrations in Patients with Septic Shock Do Not Predict Treatment Effect of Hydrocortisone on Mortality. A Nested Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 700-707.	5.6	7
29	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74
30	Reduced urinary levels of angiotensin-converting enzyme 2 activity predict acute kidney injury in critically ill patients. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 344-354.	0.1	0
31	Letter by Sajeev et al Regarding Article, "SARS-CoV-2 and Stroke in a New York Healthcare Systemâ€. Stroke, 2020, 51, e314-e315.	2.0	0
32	Classic and Nonclassic Renin-Angiotensin Systems in the Critically III. Critical Care Clinics, 2019, 35, 213-227.	2.6	67
33	May Measurement Month 2017: an analysis of blood pressure screening results from Australia—South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.1	6
34	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
35	Plasma endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular outcomes in humans. International Journal of Cardiology, 2019, 291, 168-172.	1.7	11
36	P5740ACE2 activity level is associated with embolic stroke of undetermined source. European Heart Journal, 2019, 40, .	2.2	1

#	Article	IF	CITATIONS
37	Prevalence and profile of "seasonal frequent flyers―with chronic heart disease: Analysis of 1598 patient-years follow-up. International Journal of Cardiology, 2019, 279, 126-132.	1.7	3
38	Effects of Clonidine on the Cardiovascular, Renal, and Inflammatory Responses to Experimental Bacteremia. Shock, 2019, 51, 348-355.	2.1	15
39	Development of Acute Decompensated Heart Failure Among Hospital Inpatients: Incidence, Causes and Outcomes. Heart Lung and Circulation, 2019, 28, 406-413.	0.4	2
40	Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?. Cardiac Failure Review, 2019, 5, 83-85.	3.0	15
41	Author reply. Internal Medicine Journal, 2018, 48, 228-229.	0.8	0
42	Left ventricular hypertrophy and cognitive function: a systematic review. Journal of Human Hypertension, 2018, 32, 171-179.	2.2	11
43	A17693 Investigation of the Peguero-Lo Presti Criteria to Improve the Sensitivity of the Electrocardiogram to Diagnose Left Ventricular Hypertrophy in Patients with Type 2 Diabetes. Journal of Hypertension, 2018, 36, e252.	0.5	1
44	A15912 Reduced expression of cardiac Kruppel like factor 15 is associated with cardiac hypertrophy in patients with aortic stenosis. Journal of Hypertension, 2018, 36, e236-e237.	0.5	0
45	A15943 Cerebral atrophy in patients with type 2 diabetes and left ventricular hypertrophy. Journal of Hypertension, 2018, 36, e237.	0.5	0
46	Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathy. Heart, 2018, 104, 1985.1-1985.	2.9	2
47	P6304Role of novel biomarkers to improve risk stratification in aortic stenosis: focus on plasma ACE2 activity. European Heart Journal, 2018, 39, .	2.2	0
48	P6430Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. European Heart Journal, 2018, 39, .	2.2	0
49	Routine use of HbA1c amongst inpatients hospitalised with decompensated heart failure and the association of dysglycaemia with outcomes. Scientific Reports, 2018, 8, 13564.	3.3	5
50	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. The Lancet Global Health, 2018, 6, e736-e743.	6.3	245
51	The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice. Scientific Reports, 2018, 8, 10175.	3.3	41
52	Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15. BMC Nephrology, 2018, 19, 159.	1.8	3
53	Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2698-2706.	3.6	70
54	Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy. International Journal of Molecular Sciences, 2018, 19, 1303.	4.1	10

#	Article	IF	CITATIONS
55	Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS ONE, 2018, 13, e0198144.	2.5	143
56	Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity. Oncotarget, 2018, 9, 35500-35511.	1.8	14
57	Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace, 2017, 19, euw246.	1.7	138
58	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. Current Problems in Cardiology, 2017, 42, 198-225.	2.4	17
59	Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts. EBioMedicine, 2017, 18, 171-178.	6.1	17
60	Experimental and Human Evidence for Lipocalinâ€2 (Neutrophil Gelatinaseâ€Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	59
61	Commencement of cardioselective betaâ€blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal, 2017, 47, 1043-1050.	0.8	9
62	The Peguero-Lo Presti Electrocardiographic Criteria Predict All-Cause Mortality in Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2017, 70, 1831-1832.	2.8	9
63	Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2195-2203.	2.4	67
64	A nurse practitioner program improves outcomes for patients diagnosed with heart failure. Journal for Nurse Practitioners, 2017, 13, e350.	0.8	1
65	Sacubitril/valsartan: beyond natriuretic peptides. Heart, 2017, 103, 1569-1577.	2.9	72
66	Does left ventricular hypertrophy affect cognition and brain structural integrity in type 2 diabetes? Study design and rationale of the Diabetes and Dementia (D2) study. BMC Endocrine Disorders, 2017, 17, 24.	2.2	1
67	Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS ONE, 2017, 12, e0171975.	2.5	11
68	An unusual presentation of carcinomatous meningitis. Oxford Medical Case Reports, 2016, 2016, omw068.	0.4	3
69	Angiotensin converting enzyme 2 and diminazene. Current Opinion in Nephrology and Hypertension, 2016, 25, 384-395.	2.0	38
70	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology, Journal of Clinical Hypertension, 2016, 18, 714-717.	2.0	32
71	A Call to Regulate Manufacture and Marketing of Blood Pressure Devices and Cuffs: A Position Statement From the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. Journal of Clinical Hypertension, 2016, 18, 378-380.	2.0	37
72	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. Journal of Clinical Hypertension, 2016, 18, 1082-1085.	2.0	19

#	Article	IF	CITATIONS
73	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. Hypertension, 2016, 68, 266-268.	2.7	16
74	Betaâ€blockers are underâ€prescribed in patients with chronic obstructive pulmonary disease and coâ€morbid cardiac disease. Internal Medicine Journal, 2016, 46, 1336-1340.	0.8	16
75	ISH NIA PS 01-09 ACE2 activation improves the cardiac consequences of kidney disease. Journal of Hypertension, 2016, 34, e277.	0.5	0
76	OS 36-04 KRUPPEL LIKE FACTOR 15 IS ASSOCIATED WITH CARDIAC HYPERTROPHY IN AN EXPERIMENTAL MODEL OF KIDNEY DISEASE. Journal of Hypertension, 2016, 34, e402-e403.	0.5	1
77	Impact of nurse-mediated management on achieving blood pressure goal levels in primary care: Insights from the Valsartan Intensified Primary carE Reduction of Blood Pressure Study. European Journal of Cardiovascular Nursing, 2016, 15, 409-416.	0.9	8
78	Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. International Journal of Cardiology, 2016, 212, 1-10.	1.7	43
79	A rare case of Behçet disease with generalised myositis, cardiomyositis and necrotising fasciitis. BMJ Case Reports, 2016, 2016, bcr2015211983.	0.5	7
80	The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation. PLoS ONE, 2016, 11, e0161715.	2.5	18
81	Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. PLoS ONE, 2016, 11, e0161760.	2.5	22
82	Short-Term Treatment with Diminazene Aceturate Ameliorates the Reduction in Kidney ACE2 Activity in Rats with Subtotal Nephrectomy. PLoS ONE, 2015, 10, e0118758.	2.5	36
83	MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury. American Journal of Physiology - Renal Physiology, 2015, 309, F943-F954.	2.7	17
84	Usefulness of Retinal Microvascular Endothelial Dysfunction as a Predictor of Coronary Artery Disease. American Journal of Cardiology, 2015, 115, 609-613.	1.6	39
85	Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 559-569.	1.7	70
86	Shigella sonnei bacteraemia occurring in a young man with shigellosis. BMJ Case Reports, 2015, 2015, bcr2014208875-bcr2014208875.	0.5	9
87	Comment on Venskutonyte et al. Longitudinal Development of Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes. Diabetes Care 2014;37:3092–3097. Diabetes Care, 2015, 38, e62-e63.	8.6	0
88	From gene to proteinââ,¬â€experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Frontiers in Physiology, 2014, 5, 227.	2.8	112
89	The World Hypertension League and International Society of Hypertension Call on Governments, Nongovernmental Organizations, and the Food Industry to Work to Reduce Dietary Sodium. Journal of Clinical Hypertension, 2014, 16, 99-100.	2.0	26
90	Postprandial effects of a high salt meal on serum sodium, arterial stiffness, markers of nitric oxide production and markers of endothelial function. Atherosclerosis, 2014, 232, 211-216.	0.8	49

#	Article	IF	CITATIONS
91	Retinal microvascular structure and function in patients with risk factors of atherosclerosis and coronary artery disease. Atherosclerosis, 2014, 233, 478-484.	0.8	31
92	Prevalence, predictors and evolution of echocardiographically defined cardiac abnormalities in adults with type 1 diabetes: an observational cohort study. Journal of Diabetes and Its Complications, 2014, 28, 22-28.	2.3	27
93	More rigorous protocol adherence to intensive structured management improves blood pressure control in primary care. Journal of Hypertension, 2014, 32, 1342-1350.	0.5	10
94	The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. Journal of Hypertension, 2014, 32, 446-447.	0.5	13
95	Effects of Renal Denervation on Regional Hemodynamics and Kidney Function in Experimental Hyperdynamic Sepsis. Critical Care Medicine, 2014, 42, e401-e409.	0.9	21
96	Activation of the Mas Receptor by Angiotensin-(1–7) in the Renin–Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis. Gastroenterology, 2013, 145, 874-884.e5.	1.3	85
97	Age-dependent regulation of renal vasopressin V1A and V2 receptors in rats with genetic hypertension: implications for the treatment of hypertension. Journal of the American Society of Hypertension, 2013, 7, 3-13.	2.3	14
98	The <i>ACE2</i> gene: its potential as a functional candidate for cardiovascular disease. Clinical Science, 2013, 124, 65-76.	4.3	83
99	Cardiorenal Anemia Syndrome as a Prognosticator for Death in Heart Failure. American Journal of Cardiology, 2013, 111, 1187-1191.	1.6	35
100	Progression of aortic stenosis in elderly patients over long-term follow up. International Journal of Cardiology, 2013, 167, 1226-1231.	1.7	21
101	Age adjusted Charlson Co-morbidity Index is an independent predictor of mortality over long-term follow-up in infective endocarditis. International Journal of Cardiology, 2013, 168, 5243-5248.	1.7	37
102	Emerging markers in cardiovascular disease: Where does angiotensin onverting enzyme 2 fit in?. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 551-559.	1.9	89
103	To TOE or not to TOE? That is the question in patients with portal hypertension and varices: TableÂ1. Gut, 2013, 62, 655-656.	12.1	3
104	Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 2287-2294.	0.7	57
105	Determinants of Achieving Early Blood Pressure Control with Monotherapy in a Primary Care Setting. Journal of Clinical Hypertension, 2013, 15, 674-680.	2.0	3
106	Angiotensin-(1–7) and Kidney Disease: Friend or Foe. Hypertension, 2013, 62, e10.	2.7	3
107	Angiotensin-(1–7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. American Journal of Physiology - Renal Physiology, 2013, 304, G99-G108.	3.4	23
108	Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1–7). Clinical Science, 2012, 123, 29-37.	4.3	26

#	Article	IF	CITATIONS
109	Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ, The, 2012, 345, e7156-e7156.	6.0	33
110	Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 202-209.	1.7	44
111	Association of ACE2 Genetic Variants With Blood Pressure, Left Ventricular Mass, and Cardiac Function in Caucasians With Type 2 Diabetes. American Journal of Hypertension, 2012, 25, 216-222.	2.0	72
112	Combination renin–angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clinical Science, 2012, 123, 649-658.	4.3	116
113	Global longitudinal strain is a strong independent predictor of all-cause mortality in patients with aortic stenosis. European Heart Journal Cardiovascular Imaging, 2012, 13, 827-833.	1.2	185
114	Usefulness of the Charlson Co-Morbidity Index to Predict Outcomes in Patients >60 Years Old With Aortic Stenosis During 18 Years of Follow-Up. American Journal of Cardiology, 2012, 110, 695-701.	1.6	31
115	A Comparison of Precipitants and Mortality When Acute Decompensated Heart Failure Occurs in the Community and Hospital Settings. Heart Lung and Circulation, 2012, 21, 439-443.	0.4	10
116	Normalization of ejection fraction in subjects with systolic heart failure. Is it really normal? A myocardial deformation study. International Journal of Cardiology, 2012, 154, 365-367.	1.7	8
117	Chronic kidney disease: cardiac and renal angiotensinâ€eonverting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Experimental Physiology, 2012, 97, 477-485.	2.0	51
118	The CTGF gene â^'945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes. Cardiovascular Diabetology, 2012, 11, 42.	6.8	7
119	Angiotensin onverting enzyme 2 polymorphisms and cardiovascular risk. Internal Medicine Journal, 2012, 42, 1167-1167.	0.8	1
120	Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science, 2012, 123, 225-239.	4.3	88
121	Review article: the pathophysiological roles of the renin–angiotensin system in the gastrointestinal tract. Alimentary Pharmacology and Therapeutics, 2012, 35, 414-428.	3.7	123
122	N-Terminal Pro-Brain Natriuretic Peptide and Angiotensin-Converting Enzyme-2 Levels and Their Association With Postoperative Cardiac Complications After Emergency Orthopedic Surgery. American Journal of Cardiology, 2012, 109, 1365-1373.	1.6	29
123	With the "Universal Definition,―Measurement of Creatine Kinase-Myocardial Band Rather Than Troponin Allows More Accurate Diagnosis of Periprocedural Necrosis and Infarction After Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 653-661.	2.8	114
124	Validation of rapid automated tissue synchronization imaging for the assessment of cardiac dyssynchrony in sinus and non-sinus rhythm. Europace, 2011, 13, 270-276.	1.7	4
125	Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man. American Journal of Nephrology, 2011, 34, 347-355.	3.1	38
126	Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clinical Science, 2011, 120, 335-345.	4.3	68

#	Article	IF	CITATIONS
127	Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clinical Science, 2010, 118, 269-279.	4.3	48
128	Usefulness of N-Terminal Pro–Brain Natriuretic Peptide to Predict Postoperative Cardiac Complications and Long-Term Mortality After Emergency Lower Limb Orthopedic Surgery. American Journal of Cardiology, 2010, 106, 865-872.	1.6	34
129	ACE Inhibition Reduces Infarction in Normotensive but Not Hypertensive Rats: Correlation with Cortical ACE Activity. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1520-1526.	4.3	21
130	Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1–7/MAS-1-dependent pathways. American Journal of Physiology - Renal Physiology, 2010, 299, F585-F593.	2.7	71
131	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney International, 2010, 78, 287-295.	5.2	69
132	Troponin I and NT-proBNP (N-terminal pro-Brain Natriuretic Peptide) Do Not Predict 6-Month Mortality in Frail Older Patients Undergoing Orthopedic Surgery. Journal of the American Medical Directors Association, 2010, 11, 415-420.	2.5	20
133	Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. American Journal of Physiology - Renal Physiology, 2009, 297, C98-G106.	3.4	32
134	Angiotensin-(1–7), an alternative metabolite of the renin–angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clinical Science, 2009, 117, 375-386.	4.3	90
135	Quenched Fluorescent Peptide Substrates as Tools for the Discovery of Novel Cardiovascular Disease Biomarkers. Advances in Experimental Medicine and Biology, 2009, 611, 419-422.	1.6	1
136	Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology, 2008, 58, 119-126.	1.6	6
137	Coâ€localization of angiotensinâ€converting enzyme 2â€; octomerâ€4―and CD34â€positive cells in rabbit atherosclerotic plaques. Experimental Physiology, 2008, 93, 564-569.	2.0	19
138	Angiotensinâ€converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Experimental Physiology, 2008, 93, 685-693.	2.0	122
139	Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin onverting enzyme 2 expression. Experimental Physiology, 2008, 93, 622-630.	2.0	78
140	Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1327-1338.	2.8	116
141	ACE Inhibition in Experimental Chronic Renal Failure Improves Renal Function but not Cardiac Fibrosis or Function. Heart Lung and Circulation, 2008, 17, S15-S16.	0.4	Ο
142	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2008, 114, 313-320.	4.3	53
143	Early Undernutrition Leads to Long-Lasting Reductions in Body Weight and Adiposity Whereas Increased Intake Increases Cardiac Fibrosis in Male Rats1,. Journal of Nutrition, 2008, 138, 1622-1627.	2.9	53
144	ACE2 and AT4R are present in diseased human blood vessels. European Journal of Histochemistry, 2008, 52, 39.	1.5	38

#	Article	IF	CITATIONS
145	ACE2 and Diabetic Complications. Current Pharmaceutical Design, 2007, 13, 2730-2735.	1.9	18
146	Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis. Journal of Hepatology, 2007, 47, 387-395.	3.7	142
147	Optimizing heart failure management: An Australian experience. International Journal of Cardiology, 2006, 112, 256.	1.7	1
148	Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clinical Science, 2006, 110, 109-116.	4.3	43
149	Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia. Cardiovascular Research, 2006, 71, 179-188.	3.8	6
150	Immunolocalization of ACE2 and AT2 Receptors in Rabbit Atherosclerotic Plaques. Journal of Histochemistry and Cytochemistry, 2006, 54, 147-150.	2.5	57
151	Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. Journal of Hypertension, 2005, 23, 2071-2082.	0.5	25
152	Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal, 2005, 26, 369-375.	2.2	382
153	Myocardial infarction increases ACE2 expression in rat and humans: reply. European Heart Journal, 2005, 26, 1142-1143.	2.2	2
154	An unexpected cause of macroscopic haematuria. Medical Journal of Australia, 2005, 183, 321-323.	1.7	8
155	Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut, 2005, 54, 1790-1796.	12.1	289
156	Connective Tissue Growth Factor and Cardiac Fibrosis after Myocardial Infarction. Journal of Histochemistry and Cytochemistry, 2005, 53, 1245-1256.	2.5	160
157	Lateral vs medial mitral annular tissue Doppler in the echocardiographic assessment of diastolic function and filling pressures: which should we use?. European Journal of Echocardiography, 2005, 6, 97-106.	2.3	48
158	Glomerular Permeability Defect in Hypertension Is Dependent on Renin Angiotensin System Activation. American Journal of Hypertension, 2005, 18, 844-850.	2.0	9
159	Cardiorenal Protective Effects of Vasopeptidase Inhibition with Omapatrilat in Hypertensive Transgenic (mRENâ€2)27 Rats. Clinical and Experimental Hypertension, 2004, 26, 69-80.	1.3	12
160	Diabetic Pyomyositis: An uncommon cause of a painful leg. Diabetes Care, 2004, 27, 1743-1744.	8.6	14
161	Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?. Diabetic Medicine, 2004, 21, 945-950.	2.3	20
162	ACE2, a new regulator of the renin–angiotensin system. Trends in Endocrinology and Metabolism, 2004, 15, 166-169.	7.1	292

#	Article	IF	CITATIONS
163	Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia, 2003, 46, 961-971.	6.3	61
164	A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes. Circulation Research, 2003, 92, 785-792.	4.5	401
165	Upregulation of Cardiac Insulin-like Growth Factor-I Receptor by ACE Inhibition After Myocardial Infarction: Potential Role in Remodeling. Journal of Histochemistry and Cytochemistry, 2003, 51, 831-839.	2.5	17
166	Vasopressin Receptor Expression in the Placenta. Biology of Reproduction, 2003, 69, 679-686.	2.7	19
167	Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy. Hypertension, 2003, 41, 392-397.	2.7	323
168	Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. Clinical Science, 2003, 105, 339-345.	4.3	16
169	Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition. Cardiovascular Research, 2002, 54, 51-57.	3.8	33
170	Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. Journal of Hypertension, 2002, 20, 707-714.	0.5	30
171	Up-regulation of components of the renin-angiotensin system in the bile duct–ligated rat liver. Gastroenterology, 2002, 123, 1667-1676.	1.3	179
172	Inhibition of peptidases in the control of blood pressure. Essays in Biochemistry, 2002, 38, 129-139.	4.7	5
173	Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy. Diabetes, 2002, 51, 3274-3282.	0.6	252
174	In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. Journal of Hypertension, 2001, 19, 941-946.	0.5	22
175	Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. Current Hypertension Reports, 2001, 3, S31-S33.	3.5	7
176	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney International, 2001, 60, 715-721.	5.2	75
177	Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. Journal of Hypertension, 2000, 18, 749-755.	0.5	34
178	Vasopressin V1A Receptor Antagonism Does Not Reverse Adrenocorticotrophin-Induced Hypertension In The Rat. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 866-870.	1.9	11
179	Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertension. Experimental Physiology, 2000, 85, 259S-265S.	2.0	34
180	Beneficial Renal and Cardiac Effects of Vasopeptidase Inhibition With S21402 in Heart Failure. Hypertension, 2000, 36, 1105-1111.	2.7	34

#	Article	IF	CITATIONS
181	Antihypertensive and antihypertrophic effects of omapatrilat in SHR. American Journal of Hypertension, 2000, 13, 1110-1116.	2.0	47
182	Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R872-R879.	1.8	13
183	Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Cardiovascular Research, 1999, 44, 549-555.	3.8	94
184	Localization of the Insulin-like Growth Factor System in a Rat Model of Heart Failure Induced by Myocardial Infarction. Journal of Histochemistry and Cytochemistry, 1999, 47, 649-659.	2.5	23
185	Pustular vasculitis of the hands. Australasian Journal of Dermatology, 1999, 40, 204-207.	0.7	26
186	In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat. European Journal of Pharmacology, 1999, 381, 23-30.	3.5	30
187	Susceptibility to Atrial Fibrillation: Journal of Cardiovascular Electrophysiology, 1998, 9, 423-435.	1.7	54
188	New Hormonal Blockade Strategies in Cardiovascular Disease. Scandinavian Cardiovascular Journal, 1998, 32, 61-66.	1.2	11
189	Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes Mellitus. Hypertension, 1998, 32, 778-785.	2.7	75
190	Salt Induces Myocardial and Renal Fibrosis in Normotensive and Hypertensive Rats. Circulation, 1998, 98, 2621-2628.	1.6	313
191	Effects of Neutral Endopeptidase Inhibition in the Rat Remnant Kidney Model. Kidney and Blood Pressure Research, 1998, 21, 419-424.	2.0	4
192	Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H176-H182.	3.2	26
193	Effects of Chronic AVP V2R Blockade in Congestive Heart Failure in Sheep. Advances in Experimental Medicine and Biology, 1998, 449, 445-446.	1.6	4
194	Thirst in elderly subjects. Journal of Nutrition, Health and Aging, 1998, 2, 172-7.	3.3	6
195	Chronic Vasopressin Antagonism in Two-Kidney, One-Clip Renovascular Hypertension. Clinical and Experimental Hypertension, 1997, 19, 981-991.	1.3	10
196	Inhibition of Neutral Endopeptidase, the Degradative Enzyme for Natriuretic Peptides, in rat Kidney after Oral SCH 42495. Clinical Science, 1997, 93, 43-50.	4.3	20
197	Chapter 28 Mode of action of angiotensin converting enzyme inhibitors. Principles of Medical Biology, 1997, 8, 547-560.	0.1	1
198	A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension. Drug Safety, 1997, 16, 56-65.	3.2	14

#	Article	IF	CITATIONS
199	Angiotensin and bradykinin peptides in rats with myocardial infarction. Journal of Cardiac Failure, 1997, 3, 41-52.	1.7	40
200	Angiotensin II Receptor Antagonists. Drugs and Aging, 1997, 10, 421-434.	2.7	31
201	VALIDATION OF AN ECHOCARDIOGRAPHIC ASSESSMENT OF CARDIAC FUNCTION FOLLOWING MODERATE SIZE MYOCARDIAL INFARCTION IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 570-572.	1.9	37
202	Effects of Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptides in Rats with Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1996, 28, 746-754.	1.9	40
203	Down-Regulation of Vasopressin VIA Receptor mRNA in Diabetes Mellitus in the Rat. Clinical Science, 1995, 88, 671-674.	4.3	15
204	Potent Inhibitory Effect of Sr 49059, An Orally Active Non-Peptide Vasopressin via Receptor Antagonist, on Human Arterial Coronary Bypass Graft. Clinical Science, 1995, 89, 481-485.	4.3	7
205	Differential Effects of a Novel Non-Peptide Endothelin Receptor Antagonist (Bosentan) in Rat Liver and Vasculature. Clinical Science, 1995, 89, 575-579.	4.3	4
206	Beyond ACE inhibition: new developments in drug therapy for hypertension. Medical Journal of Australia, 1995, 162, 659-661.	1.7	2
207	Attenuation of Genetic Hypertension After Short-term Vasopressin V1A Receptor Antagonism. Hypertension, 1995, 26, 828-834.	2.7	43
208	Evolution of blockade of the renin-angiotensin system. Journal of Human Hypertension, 1995, 9, 375-80.	2.2	12
209	Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat Hypertension, 1994, 23, 737-743.	2.7	57
210	EFFECTS OF ANTI-EMETICS ON WATER EXCRETION IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 59-62.	1.9	2
211	HUMAN INTERNAL MAMMARY ARTERY RESPONSES TO NON-PEPTIDE VASOPRESSIN ANTAGONISTS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 121-124.	1.9	11
212	VASCULAR ENDOTHELIN RESPONSIVENESS AND RECEPTOR CHARACTERISTICS IN VITRO AND EFFECTS OF ENDOTHELIN RECEPTOR BLOCKADE IN VIVO IN CYCLOSPORIN HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 223-226.	1.9	13
213	V1-like [Arg8]vasopressin binding sites occur in rat hepatocyte nuclei. European Journal of Pharmacology, 1994, 259, 325-329.	3.5	Ο
214	Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260). Blood Pressure, 1994, 3, 137-141.	1.5	14
215	Vascular Responses to Vasopressin Antagonists in Man and Rat. Clinical Science, 1994, 87, 389-395.	4.3	33
216	EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN V1RECEPTOR ANTAGONIST. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 388-391.	1.9	6

#	Article	IF	CITATIONS
217	Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat. Journal of Endocrinology, 1993, 138, 259-266.	2.6	21
218	Angiotensin converting enzyme inhibitors in perspective: an update. Australian Family Physician, 1993, 22, 1243-7, 1251, 1255.	0.5	1
219	Atrial natriuretic peptide inhibits fluid intake in hyperosmolar subjects. Clinical Science, 1992, 83, 35-39.	4.3	10
220	Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1991, 260, R475-R479.	1.8	12
221	Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney International, 1991, 39, 295-300.	5.2	50
222	The effect of drinking on atrial natriuretic peptide, vasopressin and thirst appreciation in hyperosmolar man. Clinical Endocrinology, 1991, 35, 229-234.	2.4	12
223	Is the fluorescein dilaurate test suitable for monitoring the effectiveness of pancreatic enzyme replacement therapy?. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 675-680.	1.2	1
224	Atrial Natriuretic Peptide Inhibits Osmotically-Stimulated Thirst in Man. Clinical Science, 1990, 78, 19P-19P.	0.0	1
225	The Effect of Hypertonic Saline Infusion on Plasma Atrial Natriuretic Peptide Concentrations in Chronic Renal Failure. Clinical Science, 1990, 79, 6P-6P.	0.0	0
226	Atrial Natriuretic Peptide Concentrations during Dehydration in the Rat. Clinical Science, 1990, 79, 14P-14P.	0.0	0
227	Autoimmune ovarian failure with elevated serum levels of luteinizing hormone and enlarged ovaries Case report. BJOC: an International Journal of Obstetrics and Gynaecology, 1990, 97, 362-364.	2.3	9
228	RELEASE OF ATRIAL NATRIURETIC PEPTIDE DURING HYPERTONIC SALINE INFUSION: THE IMPORTANCE OF POSTURE. Clinical Endocrinology, 1990, 32, 491-496.	2.4	11
229	A New Radioimmunoassay for Human Alpha Atrial Natriuretic Peptide and Its Physiological Validation. Journal of Immunoassay, 1990, 11, 159-175.	0.3	24